KMT2C Deficiency Drives the Transdifferentiation of Double-Negative Prostate Cancer to Confer Resistance to AR-Targeted Therapy
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
WB, IF and IHC images for this paper
应用场景：
创建时间：
2025-03-10
相关数据集
High-throughput profiling of mRNA from parental and Enzalutamide resistant C4-2b prostate cancer cell lines
We established an enzalutamide-resistant C4-2b prostate cell line that has an active androgen receptor by maintaining the C4-2b cell line in serially increasing concentrations of enzalutamide. Among t
NIAID Data Ecosystem90
Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence [Cell line ChIP-Seq]
In prostate cancer, androgen receptor (AR)-targeting agents are very effective in various stages of the disease. However, therapy resistance inevitably occurs and little is known about how tumor cells
NIAID Data Ecosystem70
RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway
The aim of this research was to confirm the regulatory effect of RUVBL1 on gene expression in castration resistant prostate cancer. In this research, there were six samples examined including samples
NIAID Data Ecosystem50
GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance. GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance
Genomic amplification of the androgen receptor (AR) is an established mechanism of antiandrogen resistance in prostate cancer. Here we show that the magnitude of AR signaling output, independent of AR
NIAID Data Ecosystem70
RB-N phosphorylation promotes BRD4-mediated CREB signaling hyperactivation and BET inhibitor resistance
The combination of CREB inhibitor and JQ1 could overcome the resistance to BET inhibitors in RB loss prostate cancer. Our study firstly showed that GNB1L-CREB pathway was activated after RB loss and c
NIAID Data Ecosystem50
